Education
About Us
Working with TipRanks
Follow Us
iX Biopharma Ltd. (SG:42C)
SGX:42C
42C Stock Chart & Stats
S$0.14
>-S$0.01(-4.00%)
At close: 4:00 PM EST
S$0.14
>-S$0.01(-4.00%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.25
Previous CloseN/A
Volume104.10K
Average Volume (3M)15.11M
Market Cap
S$211.08M
Enterprise ValueS$212.04M
Total Cash (Recent Filing)S$866.00K
Total Debt (Recent Filing)S$5.90M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding959,444,300
10 Day Avg. Volume11,332,920
30 Day Avg. Volume15,113,843
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)38.32
Price to Sales (P/S)1.80
P/FCF Ratio-3.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary WaferiX TechnologyOwning the WaferiX sublingual wafer platform provides a durable product-engineering edge for rapid oral delivery. A platform asset enables multiple program expansions, licensing and OEM manufacturing deals that scale revenue without recreating core R&D per indication.
Partnered Commercialization And Licensing ModelRelying on partners for distribution, licensing and contract manufacturing reduces fixed commercialization costs and accelerates market access across territories. This asset-light model supports scalable royalty and milestone income while limiting capex and direct sales expense over time.
Improving Gross Profit MarginA rising gross margin (26.26%) signals improving unit economics from product mix, pricing or manufacturing efficiencies. If sustained, higher gross margins provide room to cover operating costs and make a path toward durable profitability as revenues and partner deals expand.
Bears Say
Deep Negative Net Margin And Persistent LossesA severely negative net margin and recurring losses undermine retained capital and limit reinvestment. Persistent unprofitability forces dependence on external funding, increases dilution risk, and challenges the company's ability to self-fund R&D, regulatory filings and commercialization long-term.
High Financial LeverageVery high debt-to-equity indicates heavy reliance on borrowings, increasing interest burden and refinancing risk. Leverage constrains financial flexibility, may limit strategic investments or partner negotiations, and raises solvency concerns if operating cash flows remain weak.
Negative Operating And Declining Free Cash FlowOngoing negative operating and free cash flows, plus declining FCF growth, indicate persistent cash burn and deteriorating internal funding. This limits the company’s ability to invest in pipeline, regulatory milestones and commercialization without recurring external financing or dilutive capital raises.
iX Biopharma Ltd. News
42C FAQ
What was iX Biopharma Ltd.’s price range in the past 12 months?
iX Biopharma Ltd. lowest share price was S$0.01 and its highest was S$0.25 in the past 12 months.
What is iX Biopharma Ltd.’s market cap?
iX Biopharma Ltd.’s market cap is S$211.08M.
When is iX Biopharma Ltd.’s upcoming earnings report date?
iX Biopharma Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 185 days.
How were iX Biopharma Ltd.’s earnings last quarter?
iX Biopharma Ltd. released its earnings results on Feb 08, 2026. The company reported -S$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.002.
Is iX Biopharma Ltd. overvalued?
According to Wall Street analysts iX Biopharma Ltd.’s price is currently Overvalued.
Does iX Biopharma Ltd. pay dividends?
iX Biopharma Ltd. does not currently pay dividends.
What is iX Biopharma Ltd.’s EPS estimate?
iX Biopharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iX Biopharma Ltd. have?
iX Biopharma Ltd. has 959,444,300 shares outstanding.
What happened to iX Biopharma Ltd.’s price movement after its last earnings report?
iX Biopharma Ltd. reported an EPS of -S$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.524%.
Which hedge fund is a major shareholder of iX Biopharma Ltd.?
Currently, no hedge funds are holding shares in SG:42C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
iX Biopharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
434.78%
12-Months-Change
Fundamentals
Return on Equity
-431.07%
Trailing 12-Months
Asset Growth
-22.84%
Trailing 12-Months
Company Description
iX Biopharma Ltd.
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, and insomnia. The company is also developing Wafermine, a racemic ketamine sublingual wafer, which has completed phase-2 clinical trial for the treatment of complex regional pain syndrome, as well as psychiatric conditions, including depression; iXB 401, a sublingual semaglutide wafer that is in pre-clinical development for the treatment of Type 2 Diabetes and Obesity; SL-NAD+, a sublingual NAD+ wafer to increase the body's NAD+ levels, energy levels, and alertness; iXB 120 that has completed Phase I clinical trial for acute agitation; IXB-214, which has completed Phase I clinical trial for complex regional pain syndrome; and IXB-314 that has completed Phase I clinical trial for treatment resistant depression. In addition, it develops BnoX that is in a phase-1 clinical trial for moderate to severe pain; NAD+ for sarcopenia; iXB 321, an influenza vaccine; iXB 322, a novel low-dose interferon sublingual wafe for respiratory viral prophylaxis; and LumeniX, a sublingual glutathione wafer for skin brightening and immunity. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.
Technical Analysis
Hyphens Pharma International Ltd.
―
Pharmesis International Ltd.
―
Singapore Paincare Holdings Limited
―
Alliance Healthcare Group Ltd.
―
Beverly JCG Ltd.
―
Options Prices
Currently, No data available
---